ArticleACS applied bio materials2025
Development of Biomimetic Gelatin-Hydroxyapatite Composites Containing Doxycycline with Osteogenic Potential.
Article in ACS applied bio materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Worldwide, bone illnesses and disorders are on the rise. Artificial bone substitutes may replace autogenous bone transplants. Due to its cytocompatibility, nontoxic breakdown, infinite supply, and disease resistance, biopolymers are becoming more attractive in biomedical applications. Most graft materials used in composites lack the antibacterial properties necessary for matrix biocompatibility. This study aims to develop two hybrid polymeric composites incorporating doxycycline to enhance cell compatibility and antibacterial activity, using gelatin-Hydroxyapatite-gelatin (HA-gel) cross-linked with 1% w/v (1-ethyl-3-(3-(dimethylamino)propyl)) carbodiimide (EDC) and 0.3, 0.7, and 1.2% doxycycline. The gelatin-hydroxyapatite scaffold with 1% EDC cross-linker and 0.3% doxycycline (1.1) demonstrated reduced cytotoxicity in L929 fibroblasts and MC3T3 preosteoblastic cells. At 21 days, scaffolds increased preosteoblastic cell (MC3T3) proliferation, cell adhesion, and ALP. The
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.